Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2009
10/29/2009WO2009129577A1 Methods for radiolabelling macromolecules
10/29/2009WO2009129573A1 Nicotinamide derivatives
10/29/2009WO2009111375A3 Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
10/29/2009WO2009109855A3 Immunotherapy for unresectable pancreatic cancer
10/29/2009WO2009102909A3 Anti-cancer vaccines
10/29/2009WO2009102465A3 Continuous cell programming devices
10/29/2009WO2009099991A3 Treatment of cancer
10/29/2009WO2009099719A3 Compositions and methods for the treatment of tumor of hematopoietic origin
10/29/2009WO2009075870A9 Compounds and methods for the treatment of cancer
10/29/2009WO2009046856A3 Use of serorphin as a therapeutic agent
10/29/2009WO2009046824A3 Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis
10/29/2009WO2009043505A3 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer
10/29/2009WO2009043504A3 Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer
10/29/2009WO2009040089A3 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents
10/29/2009WO2009039996A3 Use of bradykinin alone or in combination with melanotan ii as a therapeutic agent
10/29/2009WO2009039977A3 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hbv infection
10/29/2009WO2009033781A3 Use of k237 as therapeutic agent
10/29/2009WO2009033751A3 Use of leu-enkephalin as a therapeutic agent
10/29/2009WO2009033718A3 Use of anti -inflammatory peptide 1 as a therapeutic agent
10/29/2009WO2009009173A3 Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
10/29/2009WO2009005839A3 Conjugates of compounds binding the steroid hormone receptor and their use as anticancer drugs
10/29/2009WO2007146602A8 Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
10/29/2009US20090271879 Analogues of (-)-picropodophyllin, synthesis and uses thereof
10/29/2009US20090270592 Purified TNFR preparations
10/29/2009US20090270512 Pan-Antagonists For The Androgen Receptor And Androgen Receptor Mutants Associated With Anti-Androgen Withdrawal
10/29/2009US20090270506 Crystalline structure of oxidosqualene synthase
10/29/2009US20090270492 Bryostatin analogues, synthetic methods and uses
10/29/2009US20090270491 Modulation of tudor-sn expression
10/29/2009US20090270479 Genetic and Epigenetic Alterations In the Diagnosis and Treatment of Cancer
10/29/2009US20090270466 Epothilones C, D, E, and F, Preparation and Compositions
10/29/2009US20090270458 Method of treating of demyelinating diseases or conditions
10/29/2009US20090270456 Novel chemical compounds
10/29/2009US20090270447 2-Aryl-and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof
10/29/2009US20090270445 Thiazole compounds and methods of use
10/29/2009US20090270442 Polymorphs of hydrochloride salt of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
10/29/2009US20090270441 Macrolides
10/29/2009US20090270436 Spirochromanon derivatives
10/29/2009US20090270430 Pyridopyrimidinone Inhibitors of Pl3Kalpha
10/29/2009US20090270427 Purine derivatives
10/29/2009US20090270419 Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors
10/29/2009US20090270418 Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
10/29/2009US20090270410 Benzazole analogues and uses thereof
10/29/2009US20090270397 Methods and compositions for the treatment of cancers, such as melanomas and gliomas
10/29/2009US20090270394 Cyclylamine derivatives as calcium channel blockers
10/29/2009US20090270391 THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY
10/29/2009US20090270390 Pyrimidine derivatives
10/29/2009US20090270389 Pyrimidinyl pyridone inhibitors of kinases
10/29/2009US20090270388 Fused azole-pyrimidine derivatives
10/29/2009US20090270378 Novel tetrahydropyridothiophenes
10/29/2009US20090270377 Combination cancer chemotherapy
10/29/2009US20090270376 Heterocyclic janus kinase 3 inhibitors
10/29/2009US20090270368 Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
10/29/2009US20090270363 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof
10/29/2009US20090270361 Substituted pyrazole derivatives and use thereof
10/29/2009US20090270341 Product comprising a transduction inhibitor of heterotrimeric g protein signals combined with another anti-cancer agent for therapeutic use in the treatment of cancer
10/29/2009US20090270340 Methods of administering antitumor agent comprising deoxycytidine derivative
10/29/2009US20090270317 Pharmaceutical compositions comprising bioelastomer fusion proteins
10/29/2009US20090270316 Her-2 binding antagonists
10/29/2009US20090270314 Polypeptide having anti-angiogenic activity
10/29/2009US20090270265 Molecular Characteristics of Non-Small Cell Lung Cancer
10/29/2009US20090269840 Kinase insert domain-containing receptor (KDR) specific immunoglobulin for monitoring tumor angiogenesis
10/29/2009US20090269739 Kit for detection of telomerase reverse transcriptase nucleic acids
10/29/2009US20090269422 Methods for controlling angiogenesis and cell proliferation
10/29/2009US20090269421 Coating material
10/29/2009US20090269411 Masking the taste of powders
10/29/2009US20090269390 Medical devices, polymers, compositions, and methods for delivering a haloacetate
10/29/2009US20090269373 Saposin C-DOPS: A Novel Anti-Tumor Agent
10/29/2009US20090269364 Her-2/neu multi-peptide vaccine
10/29/2009US20090269363 Method for screening peptides for use in immunotherapy
10/29/2009US20090269362 Method for Controlling Immunodominance
10/29/2009US20090269361 Constructs for delivery of therapeutic agents to neuronal cells
10/29/2009US20090269354 Quinazoline derivatives and methods of treatment
10/29/2009US20090269352 Antitumor agent comprising sulfonamide-containing heterocyclic compound combined with an angiogenesis inhibitor
10/29/2009US20090269351 Method of diagnosing and treating glioma
10/29/2009US20090269343 Dual Specific Immunotoxin for Brain Tumor Therapy
10/29/2009US20090269341 Lytic domain fusion constructs and methods of making and using same
10/29/2009US20090269340 Antibodies to oncostatin m receptor
10/29/2009US20090269336 have a high binding affinity to all five isoforms of human vascular endothelial growth factor (VEGF); for cancer, age-related macular degeneration (AMD), rheumatoid arthritis, and diabetic retinopathy
10/29/2009US20090269335 Therapeutic agent for prostate cancer
10/29/2009US20090269319 ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery
10/29/2009US20090269310 Method for obtaining human smooth muscular cells and uses thereof
10/29/2009US20090269304 Methods of treating cancer using il-21 and monoclonal antibody therapy
10/29/2009US20090269289 Use of Tellurium Compounds for Protection from Ultra-Violet Radiation
10/29/2009DE102007049630A1 New amide compounds used for therapy and/or prophylaxis of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy
10/29/2009CA2753532A1 Nicotinamide derivatives
10/29/2009CA2723185A1 Inhibitors of protein kinases
10/29/2009CA2722376A1 Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias
10/29/2009CA2722340A1 Small-molecule inhibitors of the androgen receptor
10/29/2009CA2722258A1 N-acylthiourea and n-acylurea inhibitors of the hedgehog protein signalling pathway
10/29/2009CA2722184A1 Regulatory b cells and their uses
10/29/2009CA2722075A1 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient
10/29/2009CA2722041A1 Novel five-membered ring compound
10/29/2009CA2722020A1 Improved raf inhibitors
10/29/2009CA2722018A1 Method for the prevention and treatment of cancer by inhibition of gpvi
10/29/2009CA2722007A1 Five-membered ring compound
10/29/2009CA2721919A1 Limk2 inhibitors, compositions comprising them, and methods of their use
10/29/2009CA2721858A1 Pyridazinone derivatives
10/29/2009CA2721836A1 Methods for radiolabelling macromolecules
10/29/2009CA2721575A1 Aryl-quinolyl compounds and their use
10/29/2009CA2720818A1 Substituted phenoxybenzamides
1 ... 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 ... 2211